These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21210471)

  • 1. Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?
    Tefferi A
    Cancer; 2011 Jan; 117(2):234-7. PubMed ID: 21210471
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overcoming imatinib resistance].
    Ashihara E; Maekawa T
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():399-403. PubMed ID: 17474437
    [No Abstract]   [Full Text] [Related]  

  • 6. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
    Deininger MW; Druker BJ
    Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of imatinib may be possible in chronic myelogenous leukemia.
    Barton MK
    CA Cancer J Clin; 2011; 61(2):65-6. PubMed ID: 21372196
    [No Abstract]   [Full Text] [Related]  

  • 9. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
    Hochhaus A
    Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
    [No Abstract]   [Full Text] [Related]  

  • 10. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
    Cashen A; DiPersio JF; Khoury H
    J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical pharmacokinetics of imatinib mesylate.
    Levêque D; Maloisel F
    In Vivo; 2005; 19(1):77-84. PubMed ID: 15796158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].
    Yamaguchi M; Konishi I
    Rinsho Ketsueki; 2003 Apr; 44(4):254-6. PubMed ID: 12784659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
    Ozdemir E; Koc Y; Kansu E
    Am J Hematol; 2006 Jun; 81(6):474. PubMed ID: 16680756
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib mesylate for chronic myeloid leukemia: what do we really know?
    Husereau D
    Issues Emerg Health Technol; 2002 Dec; (42):1-4. PubMed ID: 12492100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib and pregnancy.
    Ali R; Ozkalemkas F; Ozcelik T; Ozkocaman V; Ozkan A
    J Clin Oncol; 2006 Aug; 24(23):3812-3; author reply 3813. PubMed ID: 16896012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.